Recent 8-K filings for RNAZ
Highest-materiality recent filing
TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment
- Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
- Concurrent investment: DEFJ buys 223.7337 Series B Preferred at $111,740/share, raising ~$25M ($20M cash + $5M promissory note at 4% due Jan 2026).
-
TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity
Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.
-
Stockholders' equity as of March 31, 2026 was $1,251,427, below Nasdaq's $2,500,000 minimum requirement.
-
TransCode secures up to $20M flexible financing from Yorkville via SEPA and convertible notes
Up to $14M SEPA for common stock sales at 97% of lowest 3-day VWAP; up to $6M in pre-paid convertible notes at 5% discount.
-
TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal
Issued 1,136,364 shares of Series C non-voting convertible preferred to Unleash; convertible to common after stockholder approval.
-
TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer
IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.
-
TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models
Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.
-
ABCJ (parent of Polynoma) reported 2024 net loss of $16.4M and accumulated deficit of $193M.
-
TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer
Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.
-
Each share of common stock held as of Oct 20, 2025 receives one CVR; CVRs pay 50% of Net Proceeds from future Upfront or Milestone payments on TTX-MC138 program disposals.
-
TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a
16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
-
TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment
Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
-
TransCode acquires ABCJ, gets $25M investment from DEFJ, appoints new CEO
Acquired 100% of ABCJ for 83,285 common shares (9.99% of pre-close), convertible preferred, and up to $95M milestone payments.
-
TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency
Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).
-
TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025
Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.
-
TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance
Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.
-
TransCode announces $10M registered direct offering of 10.25M shares and warrants at $0.98/unit
Gross proceeds of ~$10M from sale of 10.25M shares and 10.25M warrants at $0.98/unit.
-
TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h
Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
-
TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance
Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.
-
TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024
Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.
-
TransCode shareholders approve 10M share offering and reverse stock split at special meeting
Ratified issuance of 10M shares of common stock and warrants to ThinkEquity LLC via best-efforts public offering.
-
TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued
Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).
-
Nasdaq notifies TransCode of shareholder approval violation; adds to delisting risk
Received new Nasdaq deficiency letter on Sep 23, 2024 for failing to obtain shareholder approval for a deeply discounted offering.
-
TransCode Therapeutics faces Nasdaq delisting over bid price and equity deficiencies; hearing Oct 1
Minimum Bid Price Deficiency Letter received Aug 13; stock below $1.00 for 30 consecutive days through Aug 12.
-
TransCode receives two Nasdaq deficiency notices; faces potential delisting
On Aug 13, 2024, Nasdaq notified TransCode of minimum bid price deficiency; stock closed below $1.00 for 30 consecutive days.
-
TransCode Therapeutics prices $3.0M public offering of 10M shares at $0.30
Offering of 10,000,000 common shares at $0.30 per share for gross proceeds of $3.0M.
-
TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting
Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
-
TransCode shareholders reject reverse stock split; stock plan amendment approved
Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
-
TransCode Therapeutics receives Nasdaq delisting notice; hearing set for June 25, 2024
Nasdaq delisting notice due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material